Company news

Creative Medical Technology Holdings, Inc. news in 2021

Creative Medical Technology Holdings, Inc.'s news releases, calls and decks from 2021, newest first.

View company

Creative Medical Technology Holdings, Inc. Prices $16 Million Public Offering and Uplisting to the Nasdaq Capital Market

December 2, 2021

Creative Medical Technology Holdings Announces Implementation of Reverse Stock Split in Preparation for Planned Uplisting to The Nasdaq Capital Market

November 8, 2021

Creative Medical Technology Holdings Reports Positive Data on ImmCelz™ Immunotherapy Product

October 11, 2021

Creative Medical Technology Holdings Files Provisional Patent on Novel Type 1 Diabetes Immunotherapy Using Exosomes from MyeloCelz™ Platform

September 30, 2021

Creative Medical Technology Holdings, Inc. Engages Established Contact Management Organization to Accelerate Adoption of CaverStem®

September 15, 2021

Creative Medical Technology Holdings Announces $3.8 Million Private Placement with Institutional Investors

August 8, 2021

Creative Medical Technology Holdings Announces MyeloCelz™ The Company's Second Regenerative Immunotherapy Product

July 19, 2021

Creative Medical Technology Holdings Recruits Renowned Stem Cell Clinical Trials Expert to Hyper-Accelerate FDA Clearance

June 21, 2021

Creative Medical Technology Holdings To Present ImmCelz® Subsidiary At World Stem Cell Conference

June 16, 2021

Creative Medical Technology Holdings Identifies Synergy Between ImmCelz® Regenerative Immunotherapy and Myeloid Suppressor Cells in Treatment of Type 1 Diabetes

June 8, 2021

Creative Medical Technology Holdings Expands Neurological Application of ImmCelz® into Parkinson's Disease

May 23, 2021

FDA Responds to Creative Medical Technology Holdings Regarding Its ImmCelz® IND for Stroke Treatment

May 13, 2021

Creative Medical Technology Holdings, Inc. to Launch Virtual Physician™ Focused on Telehealth Solutions for Regenerative Medicine

March 22, 2021

Creative Medical Technology Holdings, Inc. Announces FDA Acknowledgment of IND Application for ImmCelz® to Treat Stroke

March 15, 2021

Creative Medical Technology Holdings, Inc. Begins Recruitment of StemSpine® Clinical Sites

March 9, 2021

Creative Medical Technology Holdings Publishes Efficacy in Pain Reduction and Mobility in Patients with Disc Degenerative Disc Using StemSpine® Personalized Adult Stem Cell Therapy

March 3, 2021

Creative Medical Technology Holdings Provides Update on ImmCelz® FDA Application

March 2, 2021

Creative Medical Technology Holdings Files Patent on Prevention of Organ Transplant Rejection using ImmCelz®

February 15, 2021

Creative Medical Technology Holdings Identifies Cellular Mechanism of Patented OvaStem® Female Infertility/Ovarian Failure Treatment

February 9, 2021

Creative Medical Technology Holdings Recruits Internationally Renowned Kidney Expert to Scientific Advisory Board

February 7, 2021

Creative Medical Technology Holdings Identifies and Files Patent on Novel Mechanism of ImmCelz® Therapeutic Activity

January 31, 2021

Creative Medical Technology Holdings Recruits Founder of Inc 500 Clinical Trials Company Dr. Boris Reznik to Accelerate Development of ImmCelz® Through FDA

January 20, 2021

Creative Medical Technology Holdings Announces Positive Data and Patent Filing Using ImmCelz® to Treat Type 1 Diabetes

January 18, 2021

Creative Medical Technology Holdings Files Investigational New Drug Application (IND) with FDA for Treatment of Stroke using ImmCelz® Regenerative Immunotherapy

January 11, 2021

ImmCelz® Stem Cell Component Demonstrated Efficacious in FDA Double Blind Placebo Controlled Clinical Trial of Advanced COVID-19 Patients

January 5, 2021